Efficacy and Safety of Lenalidomide (Len) Versus Placebo (Pbo) in Rbc-Transfusion Dependent (Td) Patients (Pts) with Ipss Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (Mds) Without Del(5Q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (Esas): Results from a Randomized Phase 3 Study (Cc-5013-Mds-005)